Search results
Results from the WOW.Com Content Network
Metformin is the British Approved Name (BAN), the United States Adopted Name (USAN), and the International Nonproprietary Name (INN). It is sold under several brand names . Common brand names include Glucophage, Riomet, Fortamet, and Glumetza in the US. [ 176 ]
It is a highly selective dipeptidyl peptidase-4 inhibitor that is typically used as an add on treatment when the first line treatment of metformin is not achieving the expected glycemic goals; though it has been approved for use as a first line treatment when metformin cannot be used. [1]
Trade name 2018 sales (million USD) 2017 sales (million USD) 1 adalimumab: rheumatoid arthritis: Humira 19 936 18427 3 apixaban: anticoagulant: Eliquis 9872 7395 4 lenalidomide: multiple myeloma: Revlimid 9685 8187 5 nivolumab: oncology: Opdivo 7570 5763 6 pembrolizumab: oncology: Keytruda 7171 3809 7 etanercept: rheumatoid arthritis: Enbrel ...
So, for example, the best time to take metformin 500mg once a day would be after your dinner. Depending on which type of metformin you take and your dose, however, you may take metformin more than ...
GSK Pakistan equation was formed when Beecham, Glaxo Welcome and Smith Kline, all having a big name in the pharmaceutical market and that were separate entities before, merged in 2002. [4] In December 2008, GSK Pakistan acquired operations of Bristol Myers Squibb in Pakistan for approximately US$36.5 million. [5]
The pharmaceutical industry in Pakistan was estimated to be worth Rs. 748 billion (US$2.6 billion) in 2023, representing about 1% of the country's GDP. [1] The industry is largely import-dependent, with more than 90% of raw material being imported and only 12% of active pharmaceutical ingredients locally produced. [1]
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...
[4] [5] It is a combination of dapagliflozin and metformin [4] and is taken by mouth. [4] Dapagliflozin/metformin was approved for use in the European Union in January 2014, [ 3 ] in the United States in February 2014, [ 5 ] [ 6 ] and in Australia in July 2014.